ArticleFrontiers in pharmacology2026
Integrative systems biology identifies SIRT1 as a senescence-related theranostic target in atherosclerosis and poliumoside as a natural activator.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cellular senescence contributes to atherosclerotic plaque progression and instability, yet senescence-related diagnostic biomarkers and actionable targets remain incompletely defined. Purpose: To identify senescence-related diagnostic/therapeutic targets in atherosclerosis using integrative systems biology, and to prioritize natural products that modulate the lead target with experimental validation. Methods: Transcriptomic profiles from GSE21545 (126 carotid plaques and 97 paired peripheral blood mononuclear cell samples) were analyzed to identify differentially expressed genes and intersected with CellAge senescence genes. WGCNA and two machine-learning approaches (LASSO and SVM-RFE) were used for feature selection and target prioritization, followed by ROC analysis, functional enrichment, immune infiltration analysis, and PPI network construction. A natural product library (5,565 compounds) was screened against SIRT1 via hierarchical docking, MM-GBSA rescoring, and 100-ns molecular dynamics simulations. Lead compound activity was tested in H Results: We identified 255 senescence-related differentially expressed genes enriched in oxidative stress and inflammatory pathways. WGCNA and machine learning converged on 10 hub genes, with SIRT1 prioritized based on network centrality and diagnostic performance (AUC = 0.997, 95% CI: 0.992-1.000) and reduced expression in plaque samples. Virtual screening nominated Poliumoside as a high-affinity SIRT1 binder with stable binding dynamics in molecular simulations. In HUVECs, Poliumoside (40 μM) mitigated H Conclusion: This study highlights SIRT1 as a senescence-related theranostic candidate in atherosclerosis and identifies Poliumoside as a natural SIRT1 activator with endothelial protective activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.